{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:16:02Z","timestamp":1791645362245,"version":"4.3.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Implementation of a long-acting injectable antiretroviral treatment program requires substantial multidisciplinary effort, particularly for program coordination, coverage\/billing, and patient support\/retention. As our program scaled to 113 patients over 2.5 years, a total of 2.25 full-time equivalents were required. Despite operational demands, clinical outcomes were favorable, supporting real-world feasibility and scalability.<\/jats:p>","DOI":"10.1093\/ofid\/ofag116","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T12:29:04Z","timestamp":1772540944000},"source":"Crossref","is-referenced-by-count":1,"title":["Scalability Metrics and Effort Requirements for a Long-Acting Injectable Antiretroviral Treatment Program"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9894-615X","authenticated-orcid":false,"given":"Joshua P","family":"Havens","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, University of Nebraska Medical Center, College of Medicine , Omaha, Nebraska ,","place":["USA"]},{"name":"Department of Pharmacy Practice, University of Nebraska Medical Center, College of Pharmacy , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1430-0851","authenticated-orcid":false,"given":"Jennifer","family":"O\u2019Neill","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Nebraska Medical Center, College of Medicine , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Kubat","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Nebraska Medical Center, College of Medicine , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3068-3732","authenticated-orcid":false,"given":"Shawnalyn W","family":"Sunagawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Nebraska Medical Center, College of Pharmacy , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-1490","authenticated-orcid":false,"given":"Jennifer M","family":"Davis","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Nebraska Medical Center, College of Medicine , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5022-9063","authenticated-orcid":false,"given":"Nada","family":"Fadul","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Nebraska Medical Center, College of Medicine , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4521-4967","authenticated-orcid":false,"given":"Joshua","family":"Lechner","sequence":"additional","affiliation":[{"name":"Nebraska Medicine , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-2505","authenticated-orcid":false,"given":"Sara H","family":"Bares","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Nebraska Medical Center, College of Medicine , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"2026031216114905600_ofag116-B1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40265-020-01284-1","article-title":"Advances in long-acting agents for the treatment of HIV infection","volume":"80","author":"Rana","year":"2020","journal-title":"Drugs"},{"key":"2026031216114905600_ofag116-B2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/aid.2020.0126","article-title":"The LAIs are coming! implementation science considerations for long-acting injectable antiretroviral therapy in the United States: a scoping review","volume":"37","author":"Kanazawa","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2026031216114905600_ofag116-B3","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"2026031216114905600_ofag116-B4","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2020","journal-title":"Lancet"},{"key":"2026031216114905600_ofag116-B5","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2026031216114905600_ofag116-B6","doi-asserted-by":"crossref","first-page":"e0332661","DOI":"10.1371\/journal.pone.0332661","article-title":"Treatment experience of people living with HIV who transitioned from oral to long-acting injectable antiretrovirals in Puerto Rico: a qualitative study","volume":"20","author":"Velez","year":"2025","journal-title":"PLoS One"},{"key":"2026031216114905600_ofag116-B7","doi-asserted-by":"crossref","first-page":"ofaf220","DOI":"10.1093\/ofid\/ofaf220","article-title":"Clinical outcomes and perspectives of people with human immunodeficiency virus type 1 twelve months after initiation of long-acting cabotegravir and rilpivirine in an observational real-world US study (BEYOND)","volume":"12","author":"Dandachi","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026031216114905600_ofag116-B8","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/hiv.13647","article-title":"Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the injectable antiretroviral therapy feasibility study (JABS)","volume":"25","author":"John","year":"2024","journal-title":"HIV Med"},{"key":"2026031216114905600_ofag116-B9","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","article-title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial","volume":"10","author":"Ramgopal","year":"2023","journal-title":"Lancet HIV"},{"key":"2026031216114905600_ofag116-B10","doi-asserted-by":"crossref","first-page":"ofad500.1427","DOI":"10.1093\/ofid\/ofad500.1427","article-title":"1592. Real-world utilization and effectiveness of long-acting cabotegravir + rilpivirine among people with HIV with detectable viral loads at initiation: trio cohort study","volume":"10","author":"Rick","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026031216114905600_ofag116-B11","author":"Sax"},{"key":"2026031216114905600_ofag116-B12","author":"Eron"},{"key":"2026031216114905600_ofag116-B13","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1007\/s40121-023-00890-2","article-title":"Cabotegravir + rilpivirine long-acting injections for HIV treatment in the US: real world data from the OPERA cohort","volume":"12","author":"Sension","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2026031216114905600_ofag116-B14","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/cid\/ciae500","article-title":"Viral suppression rates at 48 weeks in people with HIV starting long-acting cabotegravir\/rilpivirine with initial viremia","volume":"80","author":"Hickey","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026031216114905600_ofag116-B15","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/cid\/ciaf120","article-title":"Long-acting injectable HIV therapy outcomes among persons with HIV who have adherence challenges to oral antiretroviral therapy","volume":"81","author":"Hastie","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026031216114905600_ofag116-B16","author":"Rana"},{"key":"2026031216114905600_ofag116-B17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/cid\/ciae648","article-title":"Policy recommendations to support equitable access to long-acting injectables for human immunodeficiency virus prevention and treatment: a policy paper of the Infectious Diseases Society of America and the HIV Medicine Association","volume":"82","author":"Marcus","year":"2026","journal-title":"Clin Infect Dis"},{"key":"2026031216114905600_ofag116-B18","doi-asserted-by":"crossref","first-page":"S541","DOI":"10.1093\/cid\/ciac716","article-title":"Barriers to uptake of long-acting antiretroviral products for treatment and prevention of Human Immunodeficiency Virus (HIV) in high-income countries","volume":"75","author":"Cooper","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026031216114905600_ofag116-B19","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1089\/aid.2024.0007","article-title":"Early implementation and outcomes among people with HIV who accessed long-acting injectable cabotegravir\/rilpivirine at two Ryan White clinics in the U.S. South","volume":"40","author":"Haser","year":"2024","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2026031216114905600_ofag116-B20","doi-asserted-by":"crossref","first-page":"ofac455","DOI":"10.1093\/ofid\/ofac455","article-title":"Early experience implementing long-acting injectable cabotegravir\/rilpivirine for human immunodeficiency virus-1 treatment at a Ryan White-funded clinic in the US South","volume":"9","author":"Collins","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026031216114905600_ofag116-B21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1089\/apc.2024.0067","article-title":"Perspectives among health care providers and people with HIV on the implementation of long-acting injectable cabotegravir\/rilpivirine for antiretroviral therapy in Florida","volume":"38","author":"Fisk-Hoffman","year":"2024","journal-title":"AIDS Patient Care STDS"},{"key":"2026031216114905600_ofag116-B22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/QAI.0000000000003421","article-title":"Identifying implementation determinants and strategies for long-acting injectable cabotegravir-rilpivirine in people with HIV who are virally unsuppressed","volume":"96","author":"Hickey","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026031216114905600_ofag116-B23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/JNC.0000000000000386","article-title":"Injectable long-acting cabotegravir-rilpivirine therapy for people living with HIV\/AIDS: addressing implementation barriers from the start","volume":"34","author":"Pinto","year":"2023","journal-title":"J Assoc Nurses AIDS Care"},{"key":"2026031216114905600_ofag116-B24","doi-asserted-by":"crossref","first-page":"ofad341","DOI":"10.1093\/ofid\/ofad341","article-title":"Acceptability, feasibility, and appropriateness of implementation of long-acting injectable antiretrovirals: a national survey of Ryan White clinics in the United States","volume":"10","author":"Tarfa","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026031216114905600_ofag116-B25","first-page":"qxaf016","article-title":"State-level variation in access to long-acting injectable antiretroviral therapy for HIV in the United States","volume":"3","author":"Zalla","year":"2025","journal-title":"Health Aff Sch"},{"key":"2026031216114905600_ofag116-B26","doi-asserted-by":"crossref","first-page":"e26282","DOI":"10.1002\/jia2.26282","article-title":"Long-acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP Project","volume":"27","author":"Nguyen","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"2026031216114905600_ofag116-B27","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S1473-3099(15)00152-8","article-title":"Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial","volume":"15","author":"Margolis","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2026031216114905600_ofag116-B28","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"2026031216114905600_ofag116-B29","author":"Novartis Pharmaceuticals Corporation","year":"2022"},{"key":"2026031216114905600_ofag116-B30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s43058-024-00631-7","article-title":"Patient and clinic staff perspectives on the implementation of a long-acting injectable antiretroviral therapy program in an urban safety-net health system","volume":"5","author":"Agovi","year":"2024","journal-title":"Implement Sci Commun"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag116\/67225471\/ofag116.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/3\/ofag116\/67225471\/ofag116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/3\/ofag116\/67225471\/ofag116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T20:11:56Z","timestamp":1773346316000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag116\/8505617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag116","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]},"article-number":"ofag116"}}